{"id":912087,"date":"2025-11-20T08:23:43","date_gmt":"2025-11-20T13:23:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/"},"modified":"2025-11-20T08:23:43","modified_gmt":"2025-11-20T13:23:43","slug":"clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/","title":{"rendered":"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference"},"content":{"rendered":"
\n

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th<\/sup> Annual Discovery One-on-One Investor Conference by hosting 1×1 investor meetings.<\/p>\n

\n
\n Conference Details<\/u>
\n <\/strong>
\n
\n Date:<\/strong> December 4, 2025
Location: <\/strong>New York, New York
Format:<\/strong> 1×1 meetings (contact your Benchmark Representative)<\/p>\n

\n About Clene<\/strong>
\n
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson\u2019s disease, and multiple sclerosis. CNM-Au8\u00ae<\/sup>\u00a0is an investigational first-in-class therapy that improves central nervous system cells\u2019 survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8\u00ae<\/sup>\u00a0is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit\u00a0www.clene.com<\/a>\u00a0or follow us on\u00a0X (formerly Twitter)<\/a>\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n
\n Investor Contact<\/u>
\n <\/strong>
\n
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com<\/a>
617-283-2856<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference by hosting 1×1 investor meetings. Conference Details Date: December 4, 2025Location: New York, New YorkFormat: 1×1 meetings (contact your Benchmark Representative) About Clene Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting … <\/p>\n

Continue reading “Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-912087","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference by hosting 1×1 investor meetings. Conference Details Date: December 4, 2025Location: New York, New YorkFormat: 1×1 meetings (contact your Benchmark Representative) About Clene Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting … Continue reading "Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T13:23:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference\",\"datePublished\":\"2025-11-20T13:23:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/\"},\"wordCount\":231,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/\",\"name\":\"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=\",\"datePublished\":\"2025-11-20T13:23:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Market Newsdesk","og_description":"SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference by hosting 1×1 investor meetings. Conference Details Date: December 4, 2025Location: New York, New YorkFormat: 1×1 meetings (contact your Benchmark Representative) About Clene Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, \u201cClene\u201d) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting … Continue reading \"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-20T13:23:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference","datePublished":"2025-11-20T13:23:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/"},"wordCount":231,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/","name":"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=","datePublished":"2025-11-20T13:23:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3OTEzOCM3MjczODk5IzIyNDY0NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clene-to-participate-at-the-benchmark-14th-annual-discovery-one-on-one-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/912087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=912087"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/912087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=912087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=912087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=912087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}